Search by Drug Name or NDC

NDC 00069-8730-30 Vyndamax 61 mg/1 Details

Vyndamax 61 mg/1

Vyndamax is a ORAL CAPSULE, LIQUID FILLED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is TAFAMIDIS.

MedlinePlus Drug Summary

Tafamidis is used to treat transthyretin amyloid cardiomyopathy (ATTR-CM; a condition in which a protein (transthyretin) builds up in the wall of the heart making it thicker which makes it difficult for the heart to pump blood adequately). Tafamidis is in a class of medications called transthyretin stabilizers. It works by preventing the formation of transthyretin protein deposits in the heart.

Related Packages: 00069-8730-30
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Tafamidis

Product Information

NDC	00069-8730
Product ID	0069-8730_847e5e9a-9978-4804-b542-320eba1fb9ad
Associated GPIs	40550080000120
GCN Sequence Number	079710
GCN Sequence Number Description	tafamidis CAPSULE 61 MG ORAL
HIC3	P9A
HIC3 Description	PROTEIN STABILIZERS
GCN	46258
HICL Sequence Number	045729
HICL Sequence Number Description	TAFAMIDIS
Brand/Generic	Brand
Proprietary Name	Vyndamax
Proprietary Name Suffix	n/a
Non-Proprietary Name	tafamidis
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	CAPSULE, LIQUID FILLED
Route	ORAL
Active Ingredient Strength	61
Active Ingredient Units	mg/1
Substance Name	TAFAMIDIS
Labeler Name	Pfizer Laboratories Div Pfizer Inc
Pharmaceutical Class	n/a
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA212161
Listing Certified Through	2025-12-31

Package

NDC 00069-8730-30 (00069873030)

Pricing Information	N/A
NDC Package Code	0069-8730-30
Billing NDC	00069873030
Package	30 BLISTER PACK in 1 CARTON (0069-8730-30) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0069-8730-01)
Marketing Start Date	2019-08-27
NDC Exclude Flag	N